Provide feedbackProvide feedback

Home :: Primary Care

FDA panel supports approval of Arena's lorcaserin for weight management; Arena, Eisai expand agreement for drug

Thursday, May 10 2012 | Comments
Evidence Grade 0 What's This?

Eisai Inc. and Arena Pharmaceuticals Inc. reported that a Food and Drug Administration advisory panel recommended that Arena's lorcaserin hydrochloride be approved as a weight-loss treatment. The firms said the FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 18-4, with one abstention, that--based on available data--lorcaserin's benefits outweigh its risks when used long term in a population of overweight and obese individuals. Lorcaserin is intended for weight...

Eisai Inc. and Arena Pharmaceuticals Inc. reported that a Food and Drug Administration advisory panel recommended that Arena's lorcaserin hydrochloride be approved as a weight-loss treatment.

The firms said the FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 18-4, with one abstention, that--based on available data--lorcaserin's benefits outweigh its risks when used long term in a population of overweight and obese individuals.

Lorcaserin is intended for weight management, including weight loss and maintenance of weight loss, in patients who are obese or in patients who are overweight and have at least one weight-related comorbid condition.

In January, the FDA assigned a Prescription Drug User Fee Act target date of June 27 for the lorcaserin New Drug Application (NDA). Arena submitted the original NDA for lorcaserin in December 2009, but the FDA issued a complete response letter regarding the NDA in October 2010. Arena submitted its response to the FDA's letter in December.

Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, granted Eisai exclusive rights to market and distribute lorcaserin in the United States if the drug is approved.

In separate news, Arena and Eisai expanded their marketing and supply agreement for lorcaserin to encompass most of North and South America, including Canada, Mexico and Brazil.

As stated in the original agreement, Arena will manufacture lorcaserin at its facility in Switzerland and sell the finished product to Eisai for marketing and distribution. Under the expanded agreement, Arena will receive an up-front payment and is eligible to receive regulatory and development milestone payments, as well as increased payments based on net sales of the drug in Eisai's territories.

Latest News

Meda's Dymista approved as treatment for seasonal allergy symptoms Verusmed

Wednesday, May 02 2012 | Comments
Evidence Grade 0 What's This?

The Food and Drug Administration approved Meda AB's Dymista (fluticasone propionate/azelastine hydrochloride) nasal spray for the treatment of seasonal allergic rhinitis (SAR).

Specifically, the spray, which is administered twice-daily in each nostril, is approved for the relief of SAR symptoms in patients aged 12 years or older who require treatment with both of...



Pharmanest launches early-stage trial of pain product Verusmed

Monday, April 30 2012 | Comments
Evidence Grade 0 What's This?

Pharmanest AB started a Phase I study to investigate a product called Shact as a pain reliever for women who undergo intrauterine device insertion, according to Karolinska Development AB, which owns 55 percent of Pharmanest.

The primary objective of the open-label trial is to establish the pharmacokinetic...



Nabi Biopharmaceuticals to merge with Biota Holdings Verusmed

Monday, April 23 2012 | Comments
Evidence Grade 0 What's This?

Rockland, Md.-based Nabi Biopharmaceuticals and Melbourne, Australia-based Biota Holdings Ltd. entered into a definitive merger agreement to form a new company that will be called Biota Pharmaceuticals Inc.

Under the terms of the agreement, Nabi will acquire all outstanding ordinary shares of Biota in...



Increased use of generics could eliminate $2 billion in wasted spending for workers' compensation payers, report states Verusmed

Friday, April 20 2012 | Comments
Evidence Grade 0 What's This?

Nearly all of the $2.1 billion in wasted pharmacy-related spending for workers' compensation payers last year could have been avoided if generic alternatives had been used instead of brand-name prescription drugs, a new Express Scripts Inc. report indicates.

Express Scripts used its internal data pertaining to waste per injured worker to extrapolate pharmacy-related...

Tags: Headache & Migraine




  1. No articles have been read
  1. No articles have been emailed
Videos